Skip to main content
. Author manuscript; available in PMC: 2021 May 7.
Published in final edited form as: Ann Intern Med. 2015 Sep 15;163(6):417–426. doi: 10.7326/M14-1804

Appendix Figure 4.

Appendix Figure 4.

Additional sensitivity analyses.

The influence on the incremental cost-effectiveness ratio of varying mortality RRs and incremental device costs of CRT-D (A), mortality RRs and CRT-D battery lives (B), rates of lead infection (C), and rates of lead failure (D). The solid vertical line represents the base case. CRT-D = cardiac resynchronization therapy combined with an ICD; ICD = implantable cardioverter-defibrillator; QALY = quality-adjusted life-year; RR = risk ratio.